Blood Cancer
EA4151
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
STATUS: Active
This phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Immunotherapy with rituximab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient’s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.
- INCLUSION CRITERIA FOR SCREENING (STEP 0 - PREREGISTRATION)
- Age >= 18 and =< 70 years
- Patients must have histologically confirmed mantle cell lymphoma, with cyclin D1 by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ hybridization (FISH). If patient has cyclin D1 negative mantle cell lymphoma with classical morphology and an expression profile (including SOX11+) that is otherwise indistinguishable from mantle cell lymphoma, communication with investigator is required for consideration of enrollment. The proliferation rate, using Ki-67 or MIB-1, should also be determined, but is not required until step 1 registration; patients may register to step 0 without a documented Ki-67 index
- In the opinion of the enrolling physician, patients must be felt to be a candidate for autologous stem cell transplantation
- Patient may be about to begin, be receiving or have completed induction therapy within 120 days prior to preregistration to step 0; no more than 300 days may have passed between the first day of induction therapy and preregistration to step 0 * For patients who have completed induction therapy and have been restaged, restaging evaluation must show status of partial (PR) or complete response (CR); post-induction patients with evidence of clinical disease progression are not eligible for preregistration * Up to two regimens of therapy (conventional chemotherapy, antibody therapy, or an oral regimen) are allowed as long as a continuous response was ongoing throughout therapy; overall, a partial response needs to have been achieved (using studies at the time of diagnosis as the baseline) ** NOTE: For example, a patient who started treatment with rituximab/bendamustine and was then switched to rituximab(R)-cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) (due to insufficient response or excessive toxicity) would be counted as having received 2 regimens; however, R-CHOP alternating with R-dexamethasone, high-dose cytarabine, and cisplatin (DHAP) as a planned induction regimen would count as one regimen
- Patient does not have any documented history of central nervous system (CNS) involvement by mantle cell lymphoma; this includes no evidence of parenchymal brain, spinal cord, or cerebrospinal fluid involvement; radiculopathy symptoms from nerve root compression by lymphoma do not constitute CNS involvement
- Patient must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen from the original diagnostic biopsy available for submission to Adaptive Biotechnologies for ClonoSEQ ID molecular marker identification of unique clonal immunoglobulin deoxyribonucleic acid (DNA) sequence * NOTE: If adequate tumor tissue is not available, peripheral blood collected prior to start of treatment with high disease burden (> 5%) is acceptable for molecular marker identification (ID) testing ** Adaptive Biotechnologies will forward results within fourteen (14) days of receipt of any stored (e.g. frozen or FFPE) tumor tissue specimen to the submitting institution and to the ECOG-American College of Radiology Imaging Network (ACRIN) Operations Office * NOTE: Patients for whom the molecular marker is identified will have peripheral blood collected after completion of induction (patient’s disease status is PR or CR) and submitted to Adaptive Biotechnologies for minimal residual disease (MRD) assessment ** Adaptive Biotechnologies will forward results within ten to fourteen (10-14) days of receipt of fresh peripheral blood specimen to the submitting institution and to the ECOG-ACRIN Operations Office
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): Patients must have met eligibility criteria for the screening step 0
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): The proliferation rate, using Ki-67 or MIB-1 immunohistochemistry (=< 30% versus > 30% versus “indeterminate” Ki-67 index), must be documented for a baseline tumor biopsy specimen
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): Institution has received results from Adaptive Biotechnologies as defined by one of the following criteria: * Patients are “MRD Indeterminate”: ClonoSEQ ID molecular marker assessment did not identify any unique clonal immunoglobulin DNA sequence OR * ClonoSEQ ID molecular marker assessment identified unique clonal immunoglobulin DNA sequence and MRD assessment is completed
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): Patients must have completed induction therapy within 150 days prior to registration to step 1, AND no more than 300 days may have elapsed from the first dose of induction chemotherapy (cycle 1 [C1] day 1 [D1]) given, until the last day of induction chemotherapy administered; for those assigned to Arms A, C, or D, the date of transplant (“day 0”) must not be greater than 365 days after the first dose of induction chemotherapy (C1D1) given * Patient must have received at least four (4) cycles of induction therapy * Up to two regimens of therapy (conventional chemotherapy, antibody therapy, or an oral regimen) are allowed as long as a continuous response was ongoing throughout therapy ** NOTE: For example, a patient who started treatment with rituximab/bendamustine and was then switched to R-CHOP (due to insufficient response or excessive toxicity) would be counted as having received 2 regimens; however, R-CHOP alternating with R-DHAP as a planned induction regimen would count as one regimen
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): Patients must have achieved a radiologic complete or partial remission as defined by the Lugano criteria
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): In the opinion of the enrolling physician, patients must be felt to be a candidate for autologous stem cell transplantation
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): Patients have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria: * HIV is sensitive to antiretroviral therapy * Must be willing to take effective antiretroviral therapy that has minimal overlapping toxicity and pharmacokinetic interactions with protocol therapy * No history of HIV-related opportunistic disease or acquired immune deficiency syndrome (AIDS)-defining conditions within past 12 months other than historic CD4+ T-cell counts below 200 cells/mm^3 * Expected long-term survival if lymphoma were not present
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): Patient must be disease-free >= 3 years of prior malignancies with the exception of adequately treated non-melanoma skin cancer, adequately treated in situ carcinoma, melanoma in situ post wide local excision or Mohs surgery, low grade prostate carcinoma (Gleason grade =< 6) managed with observation that has been stable for at least 6 months
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): Patient must not be pregnant or breast-feeding due to the potential for congenital abnormalities and of harm to nursing infants due to the treatment regimens used * All patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy * A patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- INCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1): Patient of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for 12 months post rituximab treatment
Saudi Arabia
Riyadh
King Faisal Specialist Hospital and Research Centre
Contact: Site Public Contact
United States
AK
Anchorage
Alaska Breast Care and Surgery LLC
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Alaska Oncology and Hematology LLC
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Alaska Women's Cancer Care
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Anchorage Associates in Radiation Medicine
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Anchorage Oncology Centre
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Anchorage Radiation Therapy Center
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Katmai Oncology Group
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Providence Alaska Medical Center
Contact: Site Public Contact
Email: AKPAMC.OncologyResearchSupport@providence.org
Fairbanks
Fairbanks Memorial Hospital
Contact: Site Public Contact
Email: Veronica.Stevenson@foundationhealth.org
AL
Birmingham
University of Alabama at Birmingham Cancer Center
Contact: Site Public Contact
Email: tmyrick@uab.edu
AZ
Kingman
Kingman Regional Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
Tucson
Banner University Medical Center - Tucson
Contact: Site Public Contact
Email: UACC-IIT@uacc.arizona.edu
University of Arizona Cancer Center-North Campus
Contact: Site Public Contact
Email: UACC-IIT@uacc.arizona.edu
University of Arizona Cancer Center-Orange Grove Campus
Contact: Site Public Contact
CA
Arroyo Grande
PCR Oncology
Contact: Site Public Contact
Email: research@sncrf.org
Burbank
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Contact: Site Public Contact
Email: Najee.Boucher@providence.org
Duarte
City of Hope Comprehensive Cancer Center
Contact: Site Public Contact
Email: becomingapatient@coh.org
La Jolla
UC San Diego Moores Cancer Center
Contact: Site Public Contact
Email: cancercto@ucsd.edu
Martinez
Contra Costa Regional Medical Center
Contact: Site Public Contact
Orange
UC Irvine Health/Chao Family Comprehensive Cancer Center
Contact: Site Public Contact
Email: ucstudy@uci.edu
San Diego
UC San Diego Medical Center - Hillcrest
Contact: Site Public Contact
Email: rhabbaba@health.ucsd.edu
San Francisco
UCSF Medical Center-Parnassus
Contact: Site Public Contact
Walnut Creek
BASS Medical Group - Lennon
Contact: Site Public Contact
Email: brenna.lindsey@bassmedicalgroup.com
CO
Aurora
Rocky Mountain Cancer Centers-Aurora
Contact: Site Public Contact
Email: info@westernstatesncorp.org
The Medical Center of Aurora
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Boulder
Boulder Community Foothills Hospital
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Boulder Community Hospital
Contact: Site Public Contact
Email: jbloomfield@co-cancerresearch.org
Rocky Mountain Cancer Centers-Boulder
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Centennial
Rocky Mountain Cancer Centers - Centennial
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Denver
Cancer Center of Colorado at Sloan's Lake
Contact: Site Public Contact
Colorado Blood Cancer Institute
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Denver Health Medical Center
Contact: Site Public Contact
Email: ccrp@co-cancerresearch.org
National Jewish Health-Main Campus
Contact: Site Public Contact
Email: glicht@co-cancerresearch.org
Presbyterian - Saint Lukes Medical Center - Health One
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Rocky Mountain Cancer Centers-Midtown
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Rocky Mountain Cancer Centers-Rose
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Rose Medical Center
Contact: Site Public Contact
Email: ccrp@co-cancerresearch.org
SCL Health Saint Joseph Hospital
Contact: Site Public Contact
Email: alan.franklin@sclhealth.org
The Women's Imaging Center
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Englewood
Mountain Blue Cancer Care Center - Swedish
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Rocky Mountain Cancer Centers - Swedish
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Swedish Medical Center
Contact: Site Public Contact
Email: info@westernstatesncorp.org
The Melanoma and Skin Cancer Institute
Contact: Site Public Contact
Email: ryan.weight@theskincancerinstitute.com
Golden
National Jewish Health-Western Hematology Oncology
Contact: Site Public Contact
Email: glicht@co-cancerresearch.org
Grand Junction
Grand Valley Oncology
Contact: Site Public Contact
Email: gvoclinicaltrials@gjhosp.org
Saint Mary's Hospital and Regional Medical Center
Contact: Site Public Contact
Email: ccrp@co-cancerresearch.org
Greeley
Banner North Colorado Medical Center
Contact: Site Public Contact
Email: BMDACCResearchCOMailbox@bannerhealth.com
Greenwood Village
Rocky Mountain Cancer Centers-Greenwood Village
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Lafayette
Good Samaritan Medical Center
Contact: Site Public Contact
Lakewood
Rocky Mountain Cancer Centers-Lakewood
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Littleton
Rocky Mountain Cancer Centers-Littleton
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Lone Tree
Rocky Mountain Cancer Centers-Sky Ridge
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Sky Ridge Medical Center
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Longmont
Rocky Mountain Cancer Centers-Longmont
Contact: Site Public Contact
Email: ResearchTracking@Centura.Org
Loveland
Banner McKee Medical Center
Contact: Site Public Contact
Email: BMDACCResearchCOMailbox@bannerhealth.com
Thornton
National Jewish Health-Northern Hematology Oncology
Contact: Site Public Contact
Email: glicht@co-cancerresearch.org
Rocky Mountain Cancer Centers-Thornton
Contact: Site Public Contact
Email: info@westernstatesncorp.org
Wheat Ridge
SCL Health Lutheran Medical Center
Contact: Site Public Contact
Email: ccrp@co-cancerresearch.org
CT
Hartford
Smilow Cancer Hospital Care Center at Saint Francis
Contact: Site Public Contact
Email: canceranswers@yale.edu
New Haven
Smilow Cancer Center/Yale-New Haven Hospital
Contact: Site Public Contact
Email: canceranswers@yale.edu
Yale University
Contact: Site Public Contact
Email: canceranswers@yale.edu
Torrington
Smilow Cancer Hospital-Torrington Care Center
Contact: Site Public Contact
Email: canceranswers@yale.edu
FL
Gainesville
University of Florida Health Science Center - Gainesville
Contact: Site Public Contact
Email: cancer-center@ufl.edu
Hollywood
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Contact: Site Public Contact
Email: OHR@mhs.net
Jacksonville
Baptist MD Anderson Cancer Center
Contact: Site Public Contact
Mayo Clinic in Florida
Contact: Site Public Contact
Miami
University of Miami Miller School of Medicine-Sylvester Cancer Center
Contact: Site Public Contact
Pembroke Pines
Memorial Hospital West
Contact: Site Public Contact
Tampa
Moffitt Cancer Center
Contact: Site Public Contact
Email: ClinicalTrials@moffitt.org
Moffitt Cancer Center - McKinley Campus
Contact: Site Public Contact
Email: ClinicalTrials@moffitt.org
Moffitt Cancer Center-International Plaza
Contact: Site Public Contact
Email: ClinicalTrials@moffitt.org
GA
Atlanta
Emory Saint Joseph's Hospital
Contact: Site Public Contact
Emory University Hospital Midtown
Contact: Site Public Contact
Emory University Hospital/Winship Cancer Institute
Contact: Site Public Contact
Augusta
Augusta University Medical Center
Contact: Site Public Contact
Email: ga_cares@augusta.edu
ID
Boise
Saint Alphonsus Cancer Care Center-Boise
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Saint Luke's Cancer Institute - Boise
Contact: Site Public Contact
Email: eslinget@slhs.org
Caldwell
Saint Alphonsus Cancer Care Center-Caldwell
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Coeur D'Alene
Kootenai Health - Coeur d'Alene
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Emmett
Walter Knox Memorial Hospital
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Fruitland
Saint Luke's Cancer Institute - Fruitland
Contact: Site Public Contact
Email: eslinget@slhs.org
Meridian
Idaho Urologic Institute-Meridian
Contact: Site Public Contact
Email: stephanie.couch@stjoeshealth.org
Saint Luke's Cancer Institute - Meridian
Contact: Site Public Contact
Email: eslinget@slhs.org
Nampa
Saint Alphonsus Cancer Care Center-Nampa
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Saint Luke's Cancer Institute - Nampa
Contact: Site Public Contact
Email: eslinget@slhs.org
Post Falls
Kootenai Clinic Cancer Services - Post Falls
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Sandpoint
Kootenai Clinic Cancer Services - Sandpoint
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Twin Falls
Saint Luke's Cancer Institute - Twin Falls
Contact: Site Public Contact
Email: eslinget@slhs.org
IL
Burr Ridge
Loyola Center for Health at Burr Ridge
Contact: Site Public Contact
Chicago
Northwestern University
Contact: Site Public Contact
Email: cancer@northwestern.edu
Rush University Medical Center
Contact: Site Public Contact
Email: clinical_trials@rush.edu
University of Chicago Comprehensive Cancer Center
Contact: Site Public Contact
Email: cancerclinicaltrials@bsd.uchicago.edu
University of Illinois
Contact: Site Public Contact
DeKalb
Northwestern Medicine Cancer Center Kishwaukee
Contact: Site Public Contact
Email: Donald.Smith3@nm.org
Geneva
Northwestern Medicine Cancer Center Delnor
Contact: Site Public Contact
Email: Donald.Smith3@nm.org
Homer Glen
Loyola Medicine Homer Glen
Contact: Site Public Contact
Lake Forest
Northwestern Medicine Lake Forest Hospital
Contact: Site Public Contact
Email: cancertrials@northwestern.edu
Maywood
Loyola University Medical Center
Contact: Site Public Contact
Melrose Park
Marjorie Weinberg Cancer Center at Loyola-Gottlieb
Contact: Site Public Contact
New Lenox
UC Comprehensive Cancer Center at Silver Cross
Contact: Site Public Contact
Email: cancerclinicaltrials@bsd.uchicago.edu
Orland Park
University of Chicago Medicine-Orland Park
Contact: Site Public Contact
Email: cancerclinicaltrials@bsd.uchicago.edu
Shiloh
Memorial Hospital East
Contact: Site Public Contact
Email: dschwab@wustl.edu
Warrenville
Northwestern Medicine Cancer Center Warrenville
Contact: Site Public Contact
Email: Donald.Smith3@nm.org
IN
Indianapolis
Indiana University/Melvin and Bren Simon Cancer Center
Contact: Site Public Contact
Email: iutrials@iu.edu
Sidney and Lois Eskenazi Hospital
Contact: Site Public Contact
Email: iutrials@iu.edu
KS
Chanute
Cancer Center of Kansas - Chanute
Contact: Site Public Contact
Email: research@viachristi.org
Dodge City
Cancer Center of Kansas - Dodge City
Contact: Site Public Contact
Email: research@viachristi.org
El Dorado
Cancer Center of Kansas - El Dorado
Contact: Site Public Contact
Email: research@viachristi.org
Fort Scott
Cancer Center of Kansas - Fort Scott
Contact: Site Public Contact
Email: Keisha.humphries@ascension.org
Independence
Cancer Center of Kansas-Independence
Contact: Site Public Contact
Email: research@viachristi.org
Kingman
Cancer Center of Kansas-Kingman
Contact: Site Public Contact
Email: research@viachristi.org
Lawrence
Lawrence Memorial Hospital
Contact: Site Public Contact
Email: Stephanie.Norris@LMH.ORG
Liberal
Cancer Center of Kansas-Liberal
Contact: Site Public Contact
Email: research@viachristi.org
Manhattan
Cancer Center of Kansas-Manhattan
Contact: Site Public Contact
Email: research@viachristi.org
McPherson
Cancer Center of Kansas - McPherson
Contact: Site Public Contact
Email: research@viachristi.org
Newton
Cancer Center of Kansas - Newton
Contact: Site Public Contact
Email: research@viachristi.org
Overland Park
University of Kansas Cancer Center-Overland Park
Contact: Site Public Contact
Email: KUCC_Navigation@kumc.edu
Parsons
Cancer Center of Kansas - Parsons
Contact: Site Public Contact
Email: research@viachristi.org
Pratt
Cancer Center of Kansas - Pratt
Contact: Site Public Contact
Email: research@viachristi.org
Salina
Cancer Center of Kansas - Salina
Contact: Site Public Contact
Email: research@viachristi.org
Wellington
Cancer Center of Kansas - Wellington
Contact: Site Public Contact
Email: research@viachristi.org
Westwood
University of Kansas Hospital-Westwood Cancer Center
Contact: Site Public Contact
Email: KUCC_Navigation@kumc.edu
Wichita
Ascension Via Christi Hospitals Wichita
Contact: Site Public Contact
Email: research@viachristi.org
Associates In Womens Health
Contact: Site Public Contact
Email: research@viachristi.org
Cancer Center of Kansas - Wichita
Contact: Site Public Contact
Email: research@viachristi.org
Cancer Center of Kansas-Wichita Medical Arts Tower
Contact: Site Public Contact
Email: research@viachristi.org
Winfield
Cancer Center of Kansas - Winfield
Contact: Site Public Contact
Email: research@viachristi.org
KY
Lexington
University of Kentucky/Markey Cancer Center
Contact: Site Public Contact
Louisville
The James Graham Brown Cancer Center at University of Louisville
Contact: Site Public Contact
Paducah
Mercy Health - Paducah Cancer Center
Contact: Site Public Contact
Email: BJWarner@mercy.com
MA
Boston
Beth Israel Deaconess Medical Center
Contact: Site Public Contact
Dana-Farber Cancer Institute
Contact: Site Public Contact
Massachusetts General Hospital Cancer Center
Contact: Site Public Contact
MD
Baltimore
Johns Hopkins University/Sidney Kimmel Cancer Center
Contact: Site Public Contact
Email: jhcccro@jhmi.edu
MI
Ann Arbor
University of Michigan Comprehensive Cancer Center
Contact: Site Public Contact
Detroit
Wayne State University/Karmanos Cancer Institute
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Farmington Hills
Weisberg Cancer Treatment Center
Contact: Site Public Contact
Email: ctoadmin@karmanos.org
Port Huron
Huron Medical Center PC
Contact: Site Public Contact
Email: research@sncrf.org
Lake Huron Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
MN
Rochester
Mayo Clinic in Rochester
Contact: Site Public Contact
MO
Chesterfield
Saint Luke's Hospital
Contact: Site Public Contact
Creve Coeur
Siteman Cancer Center at West County Hospital
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Saint Louis
SSM Health Saint Louis University Hospital
Contact: Site Public Contact
Siteman Cancer Center-South County
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Washington University School of Medicine
Contact: Site Public Contact
Email: info@siteman.wustl.edu
Saint Peters
Siteman Cancer Center at Saint Peters Hospital
Contact: Site Public Contact
Email: info@siteman.wustl.edu
MT
Anaconda
Community Hospital of Anaconda
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Billings
Billings Clinic Cancer Center
Contact: Site Public Contact
Email: research@billingsclinic.org
Saint Vincent Frontier Cancer Center
Contact: Site Public Contact
Saint Vincent Healthcare
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Bozeman
Bozeman Health Deaconess Hospital
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Butte
Saint James Community Hospital and Cancer Treatment Center
Contact: Site Public Contact
Great Falls
Benefis Sletten Cancer Institute
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Great Falls Clinic
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Helena
Saint Peter's Community Hospital
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Kalispell
Kalispell Regional Medical Center
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Missoula
Community Medical Center
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Saint Patrick Hospital - Community Hospital
Contact: Site Public Contact
Email: amy.hanneman@providence.org
NC
Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Contact: Site Public Contact
Email: cancerclinicaltrials@med.unc.edu
Charlotte
Atrium Health Pineville/LCI-Pineville
Contact: Site Public Contact
Carolinas Medical Center/Levine Cancer Institute
Contact: Site Public Contact
Novant Health Presbyterian Medical Center
Contact: Site Public Contact
Email: kashah@novanthealth.org
Clemmons
Wake Forest University at Clemmons
Contact: Site Public Contact
Concord
Atrium Health Cabarrus/LCI-Concord
Contact: Site Public Contact
Durham
Duke University Medical Center
Contact: Site Public Contact
Huntersville
Novant Health Cancer Institute - Huntersville
Contact: Site Public Contact
Email: kashah@novanthealth.org
Novant Health Presbyterian Medical Center Huntersville
Contact: Site Public Contact
Email: kashah@novanthealth.org
Kernersville
Novant Health Cancer Institute - Kernersville
Contact: Site Public Contact
Email: asmarrs@novanthealth.org
Matthews
Matthews Radiation Oncology Center
Contact: Site Public Contact
Email: kashah@novanthealth.org
Novant Health Cancer Institute - Matthews
Contact: Site Public Contact
Email: kashah@novanthealth.org
Mooresville
Novant Health Cancer Institute - Mooresville
Contact: Site Public Contact
Email: kashah@novanthealth.org
Mount Airy
Novant Health Cancer Institute - Mount Airy
Contact: Site Public Contact
Email: asmarrs@novanthealth.org
North Wilkesboro
Novant Health Cancer Institute - Wilkesboro
Contact: Site Public Contact
Email: pjordan@novanthealth.org
Salisbury
Rowan Regional Medical Center
Contact: Site Public Contact
Email: nnechiporchik@novanthealth.org
Stateville
Novant Health Cancer Institute - Statesville
Contact: Site Public Contact
Email: pjordan@novanthealth.org
Thomasville
Novant Health Cancer Institute - Thomasville
Contact: Site Public Contact
Email: pjordan@novanthealth.org
Winston-Salem
Novant Health Forsyth Medical Center
Contact: Site Public Contact
Email: pjordan@novanthealth.org
Wake Forest University Health Sciences
Contact: Site Public Contact
NE
Bellevue
Nebraska Medicine-Bellevue
Contact: Site Public Contact
Email: unmcrsa@unmc.edu
Omaha
Nebraska Medicine-Village Pointe
Contact: Site Public Contact
University of Nebraska Medical Center
Contact: Site Public Contact
Email: unmcrsa@unmc.edu
NH
Lebanon
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Contact: Site Public Contact
Email: cancer.research.nurse@dartmouth.edu
NJ
New Brunswick
Rutgers Cancer Institute of New Jersey
Contact: Site Public Contact
NV
Carson City
Carson Tahoe Regional Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
Henderson
Cancer and Blood Specialists-Henderson
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada - Henderson
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada-Horizon Ridge
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Contact: Site Public Contact
Email: research@sncrf.org
GenesisCare USA - Henderson
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Cancer Center-Henderson
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Green Valley
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Pebble
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at Seven Hills
Contact: Site Public Contact
Email: research@sncrf.org
Urology Specialists of Nevada - Green Valley
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Contact: Site Public Contact
Email: research@sncrf.org
Ann M Wierman MD LTD
Contact: Site Public Contact
Email: research@sncrf.org
Cancer and Blood Specialists-Shadow
Contact: Site Public Contact
Email: research@sncrf.org
Cancer and Blood Specialists-Tenaya
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada - Central Valley
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada - Northwest
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada - Town Center
Contact: Site Public Contact
Email: research@sncrf.org
Comprehensive Cancer Centers of Nevada-Summerlin
Contact: Site Public Contact
Email: research@sncrf.org
Desert West Surgery
Contact: Site Public Contact
Email: research@sncrf.org
GenesisCare USA - Fort Apache
Contact: Site Public Contact
Email: research@sncrf.org
GenesisCare USA - Las Vegas
Contact: Site Public Contact
Email: research@sncrf.org
GenesisCare USA - Vegas Tenaya
Contact: Site Public Contact
Email: research@sncrf.org
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Contact: Site Public Contact
Email: research@sncrf.org
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Contact: Site Public Contact
Email: research@sncrf.org
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Contact: Site Public Contact
Email: research@sncrf.org
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Contact: Site Public Contact
Email: research@sncrf.org
Hope Cancer Care of Nevada
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Cancer Center-Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Prostate Cancer Center
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Cathedral Rock
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Pecos
Contact: Site Public Contact
Email: research@sncrf.org
Las Vegas Urology - Smoke Ranch
Contact: Site Public Contact
Email: research@smcrf.org
Las Vegas Urology - Sunset
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at Charleston
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at Fort Apache
Contact: Site Public Contact
Email: research@sncrf.org
OptumCare Cancer Care at MountainView
Contact: Site Public Contact
Email: research@sncrf.org
Radiation Oncology Centers of Nevada Central
Contact: Site Public Contact
Email: research@sncrf.org
Radiation Oncology Centers of Nevada Southeast
Contact: Site Public Contact
Email: research@sncrf.org
Summerlin Hospital Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
Sunrise Hospital and Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
University Cancer Center
Contact: Site Public Contact
Email: research@sncrf.org
University Medical Center of Southern Nevada
Contact: Site Public Contact
Email: research@sncrf.org
Urology Specialists of Nevada - Central
Contact: Site Public Contact
Email: research@sncrf.org
Urology Specialists of Nevada - Northwest
Contact: Site Public Contact
Email: research@sncrf.org
Urology Specialists of Nevada - Southwest
Contact: Site Public Contact
Email: research@sncrf.org
Pahrump
Hope Cancer Care of Nevada-Pahrump
Contact: Site Public Contact
Email: research@sncrf.org
Reno
Radiation Oncology Associates
Contact: Site Public Contact
Email: research@sncrf.org
Renown Regional Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
Saint Mary's Regional Medical Center
Contact: Site Public Contact
Email: research@sncrf.org
NY
Buffalo
Roswell Park Cancer Institute
Contact: Site Public Contact
Email: askroswell@roswellpark.org
Glens Falls
Glens Falls Hospital
Contact: Site Public Contact
New York
Memorial Sloan Kettering Cancer Center
Contact: Site Public Contact
Rochester
University of Rochester
Contact: Site Public Contact
Webster
Wilmot Cancer Institute at Webster
Contact: Site Public Contact
Email: WCICTOresearch@urmc.rochester.edu
OH
Centerville
Miami Valley Hospital South
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Cincinnati
University of Cincinnati Cancer Center-UC Medical Center
Contact: Site Public Contact
Email: cancer@uchealth.com
Cleveland
Case Western Reserve University
Contact: Site Public Contact
Email: CTUReferral@UHhospitals.org
Cleveland Clinic Foundation
Contact: Site Public Contact
Email: TaussigResearch@ccf.org
Columbus
Ohio State University Comprehensive Cancer Center
Contact: Site Public Contact
Email: Jamesline@osumc.edu
Dayton
Miami Valley Hospital
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Miami Valley Hospital North
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Premier Blood and Cancer Center
Contact: Site Public Contact
Franklin
Atrium Medical Center-Middletown Regional Hospital
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
Greenville
Miami Valley Cancer Care and Infusion
Contact: Site Public Contact
Troy
Upper Valley Medical Center
Contact: Site Public Contact
Email: clinical.trials@daytonncorp.org
West Chester
University of Cincinnati Cancer Center-West Chester
Contact: Site Public Contact
Email: cancer@uchealth.com
OK
Oklahoma City
University of Oklahoma Health Sciences Center
Contact: Site Public Contact
Email: ou-clinical-trials@ouhsc.edu
OR
Baker City
Saint Alphonsus Cancer Care Center-Baker City
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Bend
Saint Charles Health System
Contact: Site Public Contact
Email: nosall@stcharleshealthcare.org
Clackamas
Clackamas Radiation Oncology Center
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Providence Cancer Institute Clackamas Clinic
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Coos Bay
Bay Area Hospital
Contact: Site Public Contact
Email: cherie.cox@bayareahospital.org
Newberg
Providence Newberg Medical Center
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Ontario
Saint Alphonsus Cancer Care Center-Ontario
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
Oregon City
Providence Willamette Falls Medical Center
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Portland
Oregon Health and Science University
Contact: Site Public Contact
Email: trials@ohsu.edu
Providence Portland Medical Center
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Providence Saint Vincent Medical Center
Contact: Site Public Contact
Email: CanRsrchStudies@providence.org
Redmond
Saint Charles Health System-Redmond
Contact: Site Public Contact
PA
Danville
Geisinger Medical Center
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu
Greensburg
UPMC Cancer Centers - Arnold Palmer Pavilion
Contact: Site Public Contact
Monroeville
UPMC Hillman Cancer Center - Monroeville
Contact: Site Public Contact
Email: haneydl@upmc.edu
Philadelphia
University of Pennsylvania/Abramson Cancer Center
Contact: Site Public Contact
Email: PennCancerTrials@careboxhealth.com
Pittsburgh
UPMC-Passavant Hospital
Contact: Site Public Contact
UPMC-Saint Clair Hospital Cancer Center
Contact: Site Public Contact
University of Pittsburgh Cancer Institute (UPCI)
Contact: Site Public Contact
Uniontown
UPMC Cancer Center-Uniontown
Contact: Site Public Contact
Email: ecog.rss@jimmy.harvard.edu
Wilkes-Barre
Geisinger Wyoming Valley/Henry Cancer Center
Contact: Site Public Contact
Email: HemonCCTrials@geisinger.edu
SC
Boiling Springs
Prisma Health Cancer Institute - Spartanburg
Contact: Site Public Contact
Charleston
Medical University of South Carolina
Contact: Site Public Contact
Email: hcc-clinical-trials@musc.edu
Clinton
Prisma Health Cancer Institute - Laurens
Contact: Site Public Contact
Easley
Prisma Health Cancer Institute - Easley
Contact: Site Public Contact
Email: Kim.Williams3@prismahealth.org
Greenville
Prisma Health Cancer Institute - Butternut
Contact: Site Public Contact
Prisma Health Cancer Institute - Eastside
Contact: Site Public Contact
Prisma Health Cancer Institute - Faris
Contact: Site Public Contact
Prisma Health Greenville Memorial Hospital
Contact: Site Public Contact
Saint Francis Cancer Center
Contact: Site Public Contact
Email: melissa_beckman@bshsi.org
Saint Francis Hospital
Contact: Site Public Contact
Email: melissa_beckman@bshsi.org
Greer
Prisma Health Cancer Institute - Greer
Contact: Site Public Contact
Seneca
Prisma Health Cancer Institute - Seneca
Contact: Site Public Contact
TN
Nashville
Vanderbilt University/Ingram Cancer Center
Contact: Site Public Contact
TX
Houston
Houston Methodist Hospital
Contact: Site Public Contact
Methodist Willowbrook Hospital
Contact: Site Public Contact
Email: ctsucontact@westat.com
Sugar Land
Houston Methodist Sugar Land Hospital
Contact: Site Public Contact
UT
American Fork
American Fork Hospital / Huntsman Intermountain Cancer Center
Contact: Site Public Contact
Email: officeofresearch@imail.org
Cedar City
Sandra L Maxwell Cancer Center
Contact: Site Public Contact
Email: officeofresearch@imail.org
Farmington
Farmington Health Center
Contact: Site Public Contact
Email: cancerinfo@hci.utah.edu
Logan
Logan Regional Hospital
Contact: Site Public Contact
Email: officeofresearch@imail.org
Murray
Intermountain Medical Center
Contact: Site Public Contact
Email: officeofresearch@imail.org
Ogden
McKay-Dee Hospital Center
Contact: Site Public Contact
Email: officeofresearch@imail.org
Provo
Utah Valley Regional Medical Center
Contact: Site Public Contact
Email: officeofresearch@imail.org
Riverton
Riverton Hospital
Contact: Site Public Contact
Email: officeofresearch@imail.org
Saint George
Saint George Regional Medical Center
Contact: Site Public Contact
Email: officeofresearch@imail.org
Salt Lake City
Huntsman Cancer Institute/University of Utah
Contact: Site Public Contact
Email: cancerinfo@hci.utah.edu
LDS Hospital
Contact: Site Public Contact
Email: officeofresearch@imail.org
Utah Cancer Specialists-Salt Lake City
Contact: Site Public Contact
Email: officeofresearch@imail.org
South Jordan
South Jordan Health Center
Contact: Site Public Contact
Email: cancerinfo@hci.utah.edu
VA
Charlottesville
University of Virginia Cancer Center
Contact: Site Public Contact
Email: uvacancertrials@hscmail.mcc.virginia.edu
VT
Berlin
Central Vermont Medical Center/National Life Cancer Treatment
Contact: Site Public Contact
Burlington
University of Vermont Medical Center
Contact: Site Public Contact
Email: rpo@uvm.edu
University of Vermont and State Agricultural College
Contact: Site Public Contact
Email: rpo@uvm.edu
WA
Aberdeen
Providence Regional Cancer System-Aberdeen
Contact: Site Public Contact
Email: deidre.dillon@providence.org
Auburn
MultiCare Auburn Medical Center
Contact: Site Public Contact
Email: research@multicare.org
Bellevue
Overlake Medical Center
Contact: Site Public Contact
Email: OHMCResearch@overlakehospital.org
Bellingham
PeaceHealth Saint Joseph Medical Center
Contact: Site Public Contact
Centralia
Providence Regional Cancer System-Centralia
Contact: Site Public Contact
Email: deidre.dillon@providence.org
Edmonds
Swedish Cancer Institute-Edmonds
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Everett
Providence Regional Cancer Partnership
Contact: Site Public Contact
Email: marilyn.birchman@providence.org
Gig Harbor
MultiCare Gig Harbor Medical Park
Contact: Site Public Contact
Email: research@multicare.org
Issaquah
Swedish Cancer Institute-Issaquah
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Kennewick
Kadlec Clinic Hematology and Oncology
Contact: Site Public Contact
Email: research@kadlecmed.org
Lacey
Providence Regional Cancer System-Lacey
Contact: Site Public Contact
Email: deidre.dillon@providence.org
Longview
PeaceHealth Saint John Medical Center
Contact: Site Public Contact
Email: kmakin-bond@peacehealth.org
Mount Vernon
Skagit Regional Health Cancer Care Center
Contact: Site Public Contact
Email: rcccclinicalresearch@skagitvalleyhospital.org
Port Townsend
Jefferson Healthcare
Contact: Site Public Contact
Puyallup
MultiCare Good Samaritan Hospital
Contact: Site Public Contact
Email: research@multicare.org
Renton
Valley Medical Center
Contact: Site Public Contact
Email: research@valleymed.org
Seattle
FHCC South Lake Union
Contact: Site Public Contact
Fred Hutchinson Cancer Center
Contact: Site Public Contact
Kaiser Permanente Washington
Contact: Site Public Contact
Email: KPWAoncologytrials@kp.org
Pacific Gynecology Specialists
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Swedish Medical Center-Ballard Campus
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Swedish Medical Center-Cherry Hill
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
Swedish Medical Center-First Hill
Contact: Site Public Contact
Email: PCRC-NCORP@Swedish.org
University of Washington Medical Center - Montlake
Contact: Site Public Contact
Sedro-Woolley
PeaceHealth United General Medical Center
Contact: Site Public Contact
Email: lkey@peacehealth.org
Shelton
Providence Regional Cancer System-Shelton
Contact: Site Public Contact
Email: deidre.dillon@providence.org
Spokane
MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
Contact: Site Public Contact
Email: research@multicare.org
MultiCare Deaconess Cancer and Blood Specialty Center - North
Contact: Site Public Contact
Email: research@multicare.org
Spokane Valley
MultiCare Deaconess Cancer and Blood Specialty Center - Valley
Contact: Site Public Contact
Email: research@multicare.org
Tacoma
Mary Bridge Children's Hospital and Health Center
Contact: Site Public Contact
Email: research@multicare.org
MultiCare Tacoma General Hospital
Contact: Site Public Contact
Email: research@multicare.org
Vancouver
PeaceHealth Southwest Medical Center
Contact: Site Public Contact
Email: kmakin-bond@peacehealth.org
Walla Walla
Providence Saint Mary Regional Cancer Center
Contact: Site Public Contact
Email: Cheryl.Dodd@providence.org
Yakima
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
Contact: Site Public Contact
Email: Memorial-ClinicalTrials@yvmh.org
Yelm
Providence Regional Cancer System-Yelm
Contact: Site Public Contact
Email: deidre.dillon@providence.org
WI
Chippewa Falls
Marshfield Clinic-Chippewa Center
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Eau Claire
Marshfield Medical Center-EC Cancer Center
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Mayo Clinic Health System-Eau Claire Clinic
Contact: Site Public Contact
Green Bay
Saint Vincent Hospital Cancer Center Green Bay
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Saint Vincent Hospital Cancer Center at Saint Mary's
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
La Crosse
Gundersen Lutheran Medical Center
Contact: Site Public Contact
Email: cancerctr@gundersenhealth.org
Ladysmith
Marshfield Medical Center - Ladysmith
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Madison
University of Wisconsin Carbone Cancer Center - University Hospital
Contact: Site Public Contact
Email: clinicaltrials@cancer.wisc.edu
Marshfield
Marshfield Medical Center
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Marshfield Medical Center-Marshfield
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Milwaukee
Medical College of Wisconsin
Contact: Site Public Contact
Minocqua
Marshfield Clinic-Minocqua Center
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Mukwonago
ProHealth D N Greenwald Center
Contact: Site Public Contact
Email: research.institute@phci.org
New Berlin
Froedtert and MCW Moorland Reserve Health Center
Contact: Site Public Contact
Oconomowoc
ProHealth Oconomowoc Memorial Hospital
Contact: Site Public Contact
Oconto Falls
Saint Vincent Hospital Cancer Center at Oconto Falls
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Rice Lake
Marshfield Medical Center-Rice Lake
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Stevens Point
Marshfield Medical Center-River Region at Stevens Point
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Sturgeon Bay
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Contact: Site Public Contact
Email: ewd_research_admin@hshs.org
Waukesha
ProHealth Waukesha Memorial Hospital
Contact: Site Public Contact
UW Cancer Center at ProHealth Care
Contact: Site Public Contact
Email: Chanda.miller@phci.org
Wausau
Marshfield Clinic-Wausau Center
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Weston
Marshfield Medical Center - Weston
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
Wisconsin Rapids
Marshfield Clinic - Wisconsin Rapids Center
Contact: Site Public Contact
Email: oncology.clinical.trials@marshfieldresearch.org
WV
Bridgeport
United Hospital Center
Contact: Site Public Contact
Email: cancertrialsinfo@hsc.wvu.edu
Martinsburg
WVUH-Berkely Medical Center
Contact: Site Public Contact
Email: cancertrialsinfo@hsc.wvu.edu
Morgantown
West Virginia University Healthcare
Contact: Site Public Contact
Email: cancertrialsinfo@hsc.wvu.edu
Parkersburg
Camden Clark Medical Center
Contact: Site Public Contact
Email: cancertrialsinfo@hsc.wvu.edu
Wheeling
Wheeling Hospital/Schiffler Cancer Center
Contact: Site Public Contact
WY
Cheyenne
Cheyenne Regional Medical Center-West
Contact: Site Public Contact
Email: ccrp@co-cancerresearch.org
Cody
Billings Clinic-Cody
Contact: Site Public Contact
Email: research@billingsclinic.org
Sheridan
Welch Cancer Center
Contact: Site Public Contact
Email: mccinfo@mtcancer.org
PRIMARY OBJECTIVE: I. To compare overall survival in mantle cell lymphoma (MCL) patients in minimal residual disease (MRD)-negative first complete remission (CR) who undergo autologous hematopoietic stem cell transplantation (auto-HCT) followed by maintenance rituximab versus (vs.) maintenance rituximab alone (without auto-HCT). SECONDARY OBJECTIVES: I. To compare progression-free survival in MCL patients in MRD-negative CR who undergo auto-HCT followed by maintenance rituximab vs. maintenance rituximab alone. II. To define the overall survival and progression-free survival at 2 and 5 years of chemosensitive but MRD-positive CR patients who undergo auto-HCT followed by 3 years of maintenance rituximab. III. To define the overall survival and progression-free survival at 2 and 5 years of chemosensitive but MRD-positive partial response (PR) patients who undergo auto-HCT followed by 3 years of maintenance rituximab. IV. To define the overall survival and progression-free survival at 2 and 5 years of MRD-negative PR patients who undergo auto-HCT followed by 3 years of maintenance rituximab. V. To define the overall survival and progression-free survival at 2 and 5 years of MRD-indeterminate patients who undergo auto-HCT followed by 3 years of maintenance rituximab. VI. To describe the rate of complications (serious infection, hospitalization, need for intravenous immune globulin) in MCL patients undergoing maintenance rituximab following auto-HCT. VII. To determine the prognostic impact of MRD status at day 100, in MCL patients who were MRD-positive (including MRD-positive CR and MRD-positive PR) prior to auto-HCT. EXPLORATORY TOBACCO USE OBJECTIVES: I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported cancer-treatment toxicity (adverse events (both clinical and hematologic) and dose modifications). II. To determine the effects of tobacco on patient-reported physical symptoms and psychological symptoms. III. To examine quitting behaviors and behavioral counseling/support and cessation medication utilization. IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients receive standard of care preparative chemotherapy and undergo auto-HCT. Beginning 100-140 days after transplant, patients receive rituximab intravenously (IV) or rituximab and hyaluronidase human subcutaneously (SC) or any approved rituximab biosimilar at the approved dose once every 8 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity. GROUP II: Patients receive standard of care induction chemotherapy. Beginning 40-180 days after completion of chemotherapy, patients receive rituximab or rituximab and hyaluronidase human or any approved rituximab biosimilar at the approved dose, as in Group I. Patients undergo positron emission tomography (PET), computed tomography (CT) or PET/CT throughout the study. Patients may undergo blood sample collection during screening and on study. Patients also may undergo bone marrow biopsy and aspirate during screening. After completion of study treatment, patients are followed up every 3 and 6 months for 10 years.
Interactive content above is from the official study record on the National Cancer Institute website, cancer.gov.
The ECOG-ACRIN Cancer Research Group designed this trial and is conducting it with funding from the National Cancer Institute through its National Clinical Trials Network.
![EA4151 Home Page](https://ecog-acrin.org/wp-content/uploads/2020/12/NO-TAG-LINE-ECOG-ACRIN_Logo_700px-wide-1.jpg)